{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastasis%2C+Neoplasm&page=2", "query": { "condition": "Metastasis, Neoplasm", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastasis%2C+Neoplasm&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T07:30:44.346Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02538510", "title": "Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Recurrent Nasopharynx Carcinoma", "Recurrent Salivary Gland Carcinoma", "Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary", "Stage III Major Salivary Gland Carcinoma", "Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage III Nasopharyngeal Carcinoma", "Stage IV Nasopharyngeal Carcinoma", "Stage IVA Major Salivary Gland Carcinoma", "Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage IVB Major Salivary Gland Carcinoma", "Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage IVC Major Salivary Gland Carcinoma", "Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2015-10-08", "completion_date": "2023-09-15", "has_results": true, "last_update_posted_date": "2024-11-26", "last_synced_at": "2026-07-23T07:30:44.346Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02538510" }, { "nct_id": "NCT01851213", "title": "FoundationOne™ Test Registry Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Neoplasm Metastasis", "Tumor" ], "interventions": [], "intervention_types": [], "sponsor": "Foundation Medicine", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 510, "start_date": "2013-03", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2016-08-09", "last_synced_at": "2026-07-23T07:30:44.346Z", "location_count": 1, "location_summary": "Spokane, Washington", "locations": [ { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01851213" }, { "nct_id": "NCT04703920", "title": "Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer", "Metastatic Castration-resistant Prostate Cancer", "Metastatic Ovarian Carcinoma", "Metastic or Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Talazoparib", "type": "DRUG" }, { "name": "Belinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2021-03-04", "completion_date": "2025-01-02", "has_results": false, "last_update_posted_date": "2025-01-23", "last_synced_at": "2026-07-23T07:30:44.346Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04703920" }, { "nct_id": "NCT05071183", "title": "A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "KRAS Mutation-Related Tumors", "Metastatic Solid Tumor", "Advanced Solid Tumor" ], "interventions": [ { "name": "TPX-0005", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Turning Point Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2021-09-23", "completion_date": "2023-03-01", "has_results": true, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-07-23T07:30:44.346Z", "location_count": 6, "location_summary": "California City, California • Denver, Colorado • Nashville, Tennessee + 2 more", "locations": [ { "city": "California City", "state": "California" }, { "city": "California City", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05071183" }, { "nct_id": "NCT00538005", "title": "Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "sorafenib tosylate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "San Diego Pacific Oncology & Hematology Associates", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2007-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-10", "last_synced_at": "2026-07-23T07:30:44.346Z", "location_count": 1, "location_summary": "Encinitas, California", "locations": [ { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538005" }, { "nct_id": "NCT00103103", "title": "Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "California Cancer Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2005-03", "completion_date": "2005-08", "has_results": false, "last_update_posted_date": "2010-10-13", "last_synced_at": "2026-07-23T07:30:44.346Z", "location_count": 5, "location_summary": "Duarte, California • Los Angeles, California • Pasadena, California + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00103103" }, { "nct_id": "NCT03324373", "title": "Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Partial or Radical Cytoreductive Nephrectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Yousef Zakharia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2019-03-20", "completion_date": "2024-08-28", "has_results": false, "last_update_posted_date": "2025-04-24", "last_synced_at": "2026-07-23T07:30:44.346Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT03324373" }, { "nct_id": "NCT06780670", "title": "Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Investigators choice of SoC", "type": "DRUG" }, { "name": "AAA817", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 443, "start_date": "2025-02-27", "completion_date": "2033-07-19", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-07-23T07:30:44.346Z", "location_count": 27, "location_summary": "Los Angeles, California • Palo Alto, California • Santa Barbara, California + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06780670" }, { "nct_id": "NCT03064854", "title": "PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "PDR001", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Canakinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2017-05-24", "completion_date": "2021-07-28", "has_results": false, "last_update_posted_date": "2022-08-15", "last_synced_at": "2026-07-23T07:30:44.346Z", "location_count": 5, "location_summary": "Fayetteville, Arkansas • Santa Monica, California • Stanford, California + 2 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03064854" }, { "nct_id": "NCT03654729", "title": "Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer", "Chemotherapy-induced Peripheral Neuropathy" ], "interventions": [ { "name": "Calmangafodipir (2 µmol/kg)", "type": "DRUG" }, { "name": "Calmangafodipir (5 µmol/kg)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Egetis Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 291, "start_date": "2018-11-07", "completion_date": "2020-08-31", "has_results": true, "last_update_posted_date": "2021-12-17", "last_synced_at": "2026-07-23T07:30:44.346Z", "location_count": 11, "location_summary": "Fresno, California • Orange City, Florida • Wichita, Kansas + 8 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Orange City", "state": "Florida" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Springfield", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03654729" } ] }